The Food and Drug Administration yesterday released new draft guidance for labeling medications that carry the risk of abuse or dependence, including but not limited to opioids, and simplifying labels with complicated usage instructions. Changes for potentially habit-forming drugs include defining terminology, such as abuse, misuse, addiction, physical dependence and tolerance, to avoid misinterpretation on labels. According to the guidance, opioid-specific labeling should include information about how health care professionals can safely decrease the dosage in physically dependent patients, with a goal of finding the balance in pain management and reduced use. For medications with detailed instructions for use, the FDA recommends patient-friendly visual guides that are consistent in content and format.

Related News Articles

Headline
Oct. 28 is National Prescription Drug Take Back Day, an opportunity for the public to safely dispose of unwanted or expired tablets, capsules, patches and…
Headline
Federal agencies last month stopped over 500 unapproved pharmaceutical products and medical devices, including opioid and other controlled substances, from…
Headline
As the House Energy and Commerce Committee works to reauthorize key programs within the Substance Use-Disorder Prevention that Promotes Opioid Recovery and…
Headline
While counseling and other services are an important part of a comprehensive treatment plan for opioid use disorder, the provision of medication should not be…
Headline
AHA today launched an updated Opioid Stewardship Hub, featuring the latest tools and resources to help hospitals and health systems address the opioid epidemic…
Headline
The Food and Drug Administration last week required certain labeling updates for opioid pain medicines in an effort to reduce unnecessary prescribing and…